Glucan drug delivery system and adjuvant

Details Glucan drug delivery system and adjuvant Glucan drug delivery system and adjuvant

1997-02-27

1998-04-21

Woodward, Michael P.

Drug, bio-affecting and body treating compositions

Nonspecific immunoeffector, per se ; or nonspecific...

514 54, 53612312, A61K 4736, A61K 3175, C07H 100

Patent

active

057414955

ABSTRACT:
The invention describes a whole .beta.-glucan drug delivery vehicle that non-specifically enhances the immune response, and is safe for human use. A drug is incorporated into a whole .beta.-glucan microparticle, and the combination is administered to an individual. The .beta.-glucan vehicle allows sustained release of the drug component while simultaneously enhancing the effectiveness of the drug by boosting the individual's endogenous immune response.

REFERENCES:
patent: 4705780 (1987-11-01), Massot et al.
patent: 4739046 (1988-04-01), DiLuzio
patent: 4741872 (1988-05-01), DeLuca et al.
patent: 4761402 (1988-08-01), Williams et al.
patent: 4810646 (1989-03-01), Jamas et al.
patent: 4857505 (1989-08-01), Arendt
J. K. Czop, "The Role of .beta.-Glucan Receptors on Blood and Tissue Leukocytes in Phagocytosis and Metabolic Activation", Pathology and Immunopathology Research 5:286-296 (1986).
Cook et al., "Immunomodulation of Protozoan Diseases", Surv. Immunol. Res. 2:243-245 (1983).
W. Browder, "Role of Immunomodulation in Sugical Infections", Surv. Immunol. Res. 2:299-301 (1983).
M. L. Patchen, "Immunomodulators and Hemopoiesis", Surv. Immunol. Res. 2:237-242 (1983).
Reynolds et al., "Glucan-Induced Enhancement of Host Resistance to Selected Infectious Diseases", Infection and Immunity 30(1):51-57 (Oct. 1980).
Holbrook et al., "Glucan-Enhanced Immunogenicity of Killed Erythrocytic Stages of Plasmodium berghei ", Infection and Immunity 32(2):542-546 (May 1981).
Benach et al., "Glucan as an Adjuvant for a Murine Babesia microti Immunization Trial", Infection and Immunity 35(3):947-951 (Mar. 1982).
Sherwood et al., "Enhancement of Interleukin-1 and Interleukin-2 Production by Soluble Glucan", Int'l J. Immunopharmac. 9(3):261-267 (1987).
Cook et al., "Protective Effect of Glucan Against Visceral Leishmaniasis in Hamsters", Infection ahd Immunity 37(3):1261-1269 (Sep. 1982).
T. Holbrook and J. Cook, "Immunization of Mice Against Leishmania Donovani by Subcutaneous Injections of Dead Promastigotes", Amer. J. Trop. Med. Hyg. 32(1):51-53 (1983).
Holbrook et al., "Immunization Against Leishmania Donovani: Glucan as an Adjuvant with Killed Promastigotes", Am. J. Trop. Med. Hyg. 30(4):762-768 (1981).
J. Cook and T. Holbrook, "Immunogenicity of Soluble and Particulate Antigens from Leishmania donovani: Effect of Glucan as an Adjuvant", Infection and Immunity 40(3):1038-1043 (Jun. 1983).
Chirigos et al., "Chemical and Biological Adjuvants Capable of Potentiating Tumor Cell Vaccine", Cancer Research 38:1085-1091 (Apr. 1978).
Jamas et al., "Morphology of Yeast Cell Wall as Affected by Genetic Manipulation of .beta.(1.fwdarw.6) Glycosidic Linkage", Biotech. and Bioeng. 28:769-784 (1986).
Patent Abstracts of Japan, "Vehicle for Slow-Releasing Drug", 8(279)(Dec. 1984).
Jamas et al., "Controlled Biosynthesis of Yeast Glucan Particles", Industrial Polysaccharides: Genetic Engineering, Structure/Property Relations and Applications Elserier Science Publ. B.V., Amsterdam N.C., 65-69 (1987).
International Search Report for International Application No. PCT/US90/03440.

Affiliated with

Also associated with

Rating

Glucan drug delivery system and adjuvant does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Glucan drug delivery system and adjuvant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glucan drug delivery system and adjuvant will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2055320